Zurich, Switzerland, July 30, 2024 – Muvon Therapeutics AG, an innovative clinical-stage biotechnology company, today announced that Marcus Droege has joined the management team as Chief Commercial Officer. Dr. Droege brings over 20 years of biopharmaceutical experience and a track record of international commercial success across global specialty medicines.
MUVON Therapeutics, a clinical-stage biotechnology company focused on developing a novel therapeutic platform for the regeneration of skeletal muscle tissue based on autologous cells today announced the appointment of Marcus Droege, PhD, MBA, as Chief Commercial Officer (CCO) effective July 1, 2024. Dr. Droege will lead the company’s global commercial strategy and operations as it prepares for its Phase 2 interim data read-out in early 2025 as the first tissue-engineered regenerative therapy for the treatment for stress urinary incontinence.
“We’re delighted to welcome Marcus to MUVON Therapeutics and look forward to adding his experience and expertise to our leadership team as we continue advancing innovative, potentially transformative treatment options for patients suffering from stress urinary incontinence,” said Deana Mohr, Chief Executive Officer at MUVON Therapeutics. “Marcus’ exceptional talent for unifying teams around a shared vision and promoting a culture of performance and innovation will significantly enhance our emerging global commercial business and corporate development activities.”
“This is a great time to join MUVON Therapeutics as the company has the opportunity to offer a first-in-class therapeutic option to patients with stress urinary incontinence, a condition that affects over 200 million people worldwide with severe impact on physical and mental health,” said Marcus Droege. “I look forward to working alongside the executive leadership team and continuing the ongoing efforts to build out the company’s commercial strategies and capabilities.”
Dr. Droege comes to MUVON Therapeutics after contributing to global launches of highly transformative specialty medicines across multiple therapeutic areas at both small biotech and large pharmaceutical companies. He most recently led global value & market access activities at Passage Bio after extensive cell & gene therapy launch experience at AveXis, bluebird bio, and earlier, Novartis in the United States and Europe. He began his career in clinical development, medical affairs, and commercial roles at Takeda.
He has wide-ranging proficiency working with regulators, global payers and HTA organizations in the U.S., Europe, APAC region, and South America. His extensive experience includes direct U.S. payer account management responsibility (both commercial and government), the development and execution of pricing strategies for Advanced Therapy Medicinal Products (ATMPs) in global markets and working directly with health technology assessment HTA organizations in key European and international regions.
For more information, please contact:
Dr. Deana Mohr, CEO
About Muvon Therapeutics AG
Founded in 2020, Muvon Therapeutics is a clinical-stage life science spin-off from the University of Zurich currently being accelerated by the Wyss Zurich Translational Center. Muvon Therapeutics is dedicated to the discovery and development of personalized regenerative treatments with the goal of establishing them as an affordable standard of care, with an initial focus on the treatment of stress urinary incontinence in women. Our mission is to help the millions of patients suffering from serious debilitating diseases regain control of their lives by offering them minimally invasive treatment for regeneration of skeletal muscle tissue. For more information about Muvon Therapeutics, please visit: www.muvon-therapeutics.com
Comments